HLS 21RS-380 ENGROSSED

2021 Regular Session

HOUSE BILL NO. 316

14

15

16

17

18

19

20

BY REPRESENTATIVE DAVIS

Prefiled pursuant to Article III, Section 2(A)(4)(b)(i) of the Constitution of Louisiana.

CHILDREN/NEWBORNS: Adds mucopolysaccharidosis type I and glycogen storage disorder type II to the state's newborn screening panel

1 AN ACT 2 To amend and reenact R.S. 40:1081.2(A)(1), relative to the state's newborn screening panel; 3 to add mucopolysaccharidosis type I and glycogen storage disorder type II to the 4 panel; to provide an effective date; and to provide for related matters. 5 Be it enacted by the Legislature of Louisiana: 6 Section 1. R.S. 40:1081.2(A)(1) is hereby amended and reenacted to read as follows: 7 §1081.2. Tests 8 A.(1) The physician attending a newborn child, or the person attending a 9 newborn child who was not attended by a physician, shall cause the child to be subjected to tests for phenylketonuria, congenital hypothyroidism, sickle cell 10 11 diseases, biotinidase deficiency, congenital adrenal hyperplasia, carnitine uptake 12 defect, long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, medium-chain 13

defect, long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, medium-chain acyl-CoA dehydrogenase deficiency, trifunctional protein deficiency, very long-chain acyl-CoA dehydrogenase deficiency, glutaric acidemia type I, 3-hydroxy-3-methylglutaryl-CoA lyase deficiency, isovaleric acidemia, 3-methylcrotonyl-CoA carboxylase deficiency, methylmalonic acidemia (CBL A,B), beta ketothiolase, methylmalonic acidemia (MUT), propionic acidemia, multiple carboxylase deficiency, argininosuccinate acidemia, citrullinemia type I, homocystinuria, maple syrup urine disease, tyrosinemia type I, mucopolysaccharidosis type I (MPS I), glycogen storage disorder type II (Pompe), and other genetic conditions that have

Page 1 of 2

CODING: Words in struck through type are deletions from existing law; words <u>underscored</u> are additions.

1 been approved by the Louisiana Department of Health; however, no such tests shall 2 be given to any child whose parents object thereto. Effective July 1, 2007, cystic 3 fibrosis shall be included in the tests that the newborn child shall be subject to by the 4 physician attending the newborn child or the person attending the newborn child who 5 was not attended by a physician. 6 7 Section 2. The provisions of Section 1 of this Act supersede the provisions of Section 8 1 of Act. No. 507 of the 2016 Regular Session of the Legislature which amend R.S. 9 40:1081.2(A)(1). 10 Section 3. This Act shall become effective on January 1, 2022.

DIGEST

The digest printed below was prepared by House Legislative Services. It constitutes no part of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

HB 316 Engrossed

2021 Regular Session

Davis

Abstract: Provides that mucopolysaccharidosis type I (MPS I) and glycogen storage disorder type II (Pompe) diseases shall be added to the list of genetic conditions tested by physicians attending newborn children.

<u>Present law</u> provides that a physician attending to the care of a newborn child shall cause the child to be subjected to a list of genetic conditions provided for in <u>present law</u> that have been approved by the La. Dept. of Health. Further provides that the genetic conditions shall be tested upon approval by the newborn child's parents.

<u>Proposed law</u> retains <u>present law</u> and adds that of the genetic conditions provided by <u>present law</u>, MPS I and Pompe diseases shall be genetic conditions approved by the La. Dept. of Health and shall be tested by physicians attending newborn children, upon the approval by the child's parents.

<u>Proposed law</u> supersedes amendments to <u>present law</u>, R.S. 40:1081.2(A)(1), made by §1 of Act No. 507 of the 2016 Regular Session.

Effective Jan. 1, 2022.

(Amends R.S. 40:1081.2(A)(1))